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DNA methylation (DNAm) is known to play a pivotal role in childhood health and development, but a 
comprehensive characterization of genome-wide DNAm trajectories across this age period is 
currently lacking. We have therefore performed a series of epigenome-wide association studies in 
5,019 blood samples collected at multiple time-points from birth to late adolescence from 2,348 
participants of two large independent cohorts. DNAm profiles of autosomal CpG sites (CpGs) were 
generated using the Illumina Infinium HumanMethylation450 BeadChip. Change over time was 
widespread, observed at over one-half (53%) of CpGs. In most cases DNAm was decreasing (36% of 
CpGs). Inter-individual variation in linear trajectories was similarly widespread (27% of CpGs). 
Evidence for nonlinear change and inter-individual variation in nonlinear trajectories was somewhat 
less common (11% and 8% of CpGs, respectively). Very little inter-individual variation in change was 
explained by sex differences (0.4% of CpGs) even though sex-specific DNAm was observed at 5% of 
CpGs. DNAm trajectories were distributed non-randomly across the genome. For example, CpGs with 
decreasing DNAm were enriched in gene bodies and enhancers and were annotated to genes 
enriched in immune-developmental functions. By contrast, CpGs with increasing DNAm were 
enriched in promoter regions and annotated to genes enriched in neurodevelopmental functions. 
These findings depict a methylome undergoing widespread and often nonlinear change throughout 
childhood. They support a developmental role for DNA methylation that extends beyond birth into 
late adolescence and has implications for understanding life-long health and disease. DNAm 




EWAS, longitudinal, ageing, DNA methylation, change, childhood, trajectories, inter-individual 
variation, Generation R, ALSPAC   
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DNA methylation (DNAm), an epigenetic process whereby DNA is modified by the addition of methyl 
groups, has gained increasing attention over the past few decades, due to its pivotal role in 
development. In utero, DNAm is involved in a range of essential processes including cell 
differentiation1-3, X-chromosome inactivation4 and fetal growth5. Its role extends well beyond birth, 
e.g. by maintaining cell type identity and genome stability6-8, responding to environmental 
exposures9-11, and its involvement in immune12 and neural development13. Since it is influenced by 
both genetic and environmental factors14,15, DNAm has also emerged as a key mechanism of interest 
for understanding the gene-environmental interplay in normal ageing and disease development.  
 Numerous studies have identified strong associations between DNAm and age. While most 
have relied on cross-sectional data16-18, but a few have utilized longitudinal measurements of DNAm 
within individuals19-23. Longitudinal measurements allow one to distinguish intra-individual change 
from inter-individual differences in change, thereby greatly improving the power to detect change 
over time and to identify differences between individuals24. Identifying and characterizing CpGs for 
which DNAm changes differently over time between individuals (i.e. inter-individual variation in 
change) is a necessary step in identifying genetic and environmental influences on the methylome as 
well as their potential impact on health outcomes25. Moreover, longitudinal designs facilitate the 
study of nonlinear trajectories26,27, which might help to identify sensitive periods for DNAm change in 
development. To date, the largest epigenome-wide longitudinal study on DNAm included 385 elderly 
individuals who were followed up to five times over a maximum period of 18 years, identifying 
DNAm change at 1,316 CpG (Cytosine-phosphate-Guanine) sites19 and inter-individual variation at 
change at 570 CpGs20. Yet, little is known about DNAm trajectories across early development, as 
existing studies in childhood DNAm typically have been limited by small sample sizes21,23, short time-
periods22,28 or focused on specific CpGs in relation to maternal smoking29, birthweight30, or maternal 
BMI31.  
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 In the current study, we aim to provide a benchmark of typical epigenome-wide age-related 
DNAm trajectories within individuals, spanning the first two decades of life. This study combines 
repeated measurements of DNAm at nearly half a million CpG sites across the genome from two 
large population-based cohorts, the Generation R Study and Avon Longitudinal Study of Parents and 
Children (ALSPAC), to form one integrated dataset with four time-points of measurement. In a series 
of three epigenome-wide mixed model analyses we study linear (Model 1), nonlinear (Model 2) and 
sex-related (Model 3) trajectories of change across development. Further, we aim to identify CpGs 
for which trajectories vary between individuals (Model 1 and 2). Results are interpreted in the 
context of CpG location and biological pathways. The key findings are discussed here, full results per 
CpG can be freely accessed and visualized at http://epidelta.mrcieu.ac.uk/ [note to reviewers: this is 
a demo website for now].  
 
Results 
Cross-cohort comparability  
Sample characteristics of 1,399 Generation R participants (total DNAm samples=2,333) and of 949 
ALSPAC participants (total DNAm samples=2,686; Figure 1) are provided in Supplementary Table 1. 
After the DNAm datasets of the two cohorts underwent joint functional normalization (see 
Supplementary Figure 1 for distributions of mean DNAm levels), within-cohort stability of DNAm at 
birth and 6 or 7 years (in Generation R and ALSPAC, respectively) was compared. Stability of DNAm at 
individual CpG sites (437,864 autosomal sites) was estimated in three ways: relative concordance 
using Spearman correlations between time points, absolute concordance using intraclass correlations 
between time points (children with data for both time points: n Generation R=476, n ALSPAC=826), 
and change over time using change estimates from a linear mixed model (Model 1, online Methods) 
applied within each cohort (children with data for at least one of the two time-points: n Generation 
R=1,394, n ALSPAC=944). Estimates of all stability measures for both cohorts are depicted in Figure 2. 
Next, agreement of these stability estimates between the two cohorts was estimated with the 
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Spearman (ρ) or Pearson (r) correlation (depending on normality of the data) across all CpGs, 
between the datasets. The Spearman correlation of the relative concordance was ρ=0.62, the 
Pearson correlation of the absolute concordance was ρ=0.60, and the Pearson correlation of the 
change estimates was r=0.86, indicating strong agreement between datasets. Based on these results 
the two datasets were joined to form one set with four different time-points of DNAm (birth, age 6/7 
years, 10 years, 17 years).  
 
 
Figure 1. Longitudinal sample sizes. Sample sizes for (a) Generation R (N total children=1,399, N total 
DNAm samples=2,333); and (b) ALSPAC (N total children=949, N total DNAm samples=2,686). Bolded 
numbers represent total sample size at each time-point; non-bolded number refer to overlapping 
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Figure 2. Scatterplots of within-cohort stability of DNA methylation. Showing (a) Spearman 
correlations, (b) intraclass correlation coefficients and (c) change estimates from birth to 6/7 years 
per CpG for Generation R and ALSPAC. 
 
Linear DNAm change from birth to early adulthood 
Estimates of overall change in DNAm from birth to early adolescence (Model 1; see online Methods) 
indicated linear change at 51.6% of CpGs at a Bonferroni-corrected threshold (P<1x10-07) (Figure 3a 
and 3b). Specifically, DNAm decreased over time at 35.5% of all CpGs and increased at 16.0%. The 
mode intercept indicated that the decreasing CpGs were 88% methylated at birth (Figure 4). DNAm 
levels for increasing CpGs typically started at 5%.  
 The mode estimate DNAm change was b=-9.24x10-04 (with corresponding mode SE=6.85x10-
05), indicating an overall 0.09% DNAm decrease per year at a typical CpG site. This translates into a 
1.66% decrease in DNAm over the course of 18 years. An example of a CpG site with a typical change 
in DNAm is depicted in Figure 3a. The largest observed absolute change in DNAm was b=-3.47x10-02 
(SE=3.65x10-04, P<9.88x10-324), indicating an overall DNAm decrease of 62.5% over 18 years (Figure 
3b). Only twenty-two CpGs showed an absolute change >50% over the course of 18 years 
(Supplementary Table 2). From this it follows that typically in (cord-/peripheral) blood tissue, DNAm 
levels for CpGs do not change from a fully unmethylated to fully methylated state, or vice versa, over 
the course of 18 years.  
 Further, we observed substantial inter-individual variation in linear DNAm changes over time 
at 27.4% of all CpGs (i.e. random slope variance was greater than zero at Bonferroni-corrected 
threshold P<1x10-07; Figure 3c). On average, this variation accounted for 2.7% (SD=1.5%) of all 
estimated inter-individual variation (for intercept, age, batch, and residual) at these CpGs. At 17.3% 
of all CpGs, we observed both change and inter-individual variation in change.  
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Figure 3. DNAm levels of selected CpG sites across childhood. Parts (a-c) show CpG sites with linear 
change over time (Model 1). A typical site is shown in (a), the site with the largest observed change in 
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(b) and with inter-individual variation in DNAm change (c). Parts (d-f) show CpG sites with non-linear 
change (Model 2). A Positive-Neutral trajectory is shown in (d), a Negative-Neutral trajectory in (e) 
and a Positive-More Positive-Less Positive in (f). Parts (g-i) show CpG sites with inter-individual 
variation in change (Model 2). A site with slope variation from birth is shown in (g), slope change 
variation at 6 in (h) and slope change variation at 9 in (i). Parts (j-l) show CpG sites with sex-specific 
DNAm. A site with stable sex differences is shown in (Model 3) (j), sex-specific slope in (Model 3) (k) 




Figure 4. Overview of results from the three models. Model 1 (M1) was applied for overall change in 
DNA methylation and inter-individual variation in linear change; Model 2 (M2) for nonlinear change 
in DNA methylation and inter-individual variation in nonlinear change; and Model 3 (M3) for stable 
sex differences in DNA methylation and sex differences in change of DNA methylation (Sex by Time 
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interaction). Percentages represent percentage of autosomal CpGs below Bonferroni-corrected 
threshold (P<1x10-07).  
 
 
Figure 5. Density plots of intercepts of CpGs. Intercepts for CpGs with (a) directions of change in 
Model 1 (n=473,864); (b) nonlinear trajectories in Model 2 (n=52,043); (c) stable sex differences in 
Model 3 (n=22,821); (d) sex differences in DNAm change in Model 3 (n=1,768).  
 
 
Nonlinear DNAm change  
Model 2 (see online Methods) was identical to Model 1 but permitted slope changes at ages 6 and 9 
years to test for nonlinear DNAm trajectories. At 11.0% of CpGs a nonlinear trajectory was detected. 
Specifically, at 4.8% of all CpGs, DNAm increased from birth and remained stable from 6 onward 
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(Positive-Neutral; Figure 3d). Second, at 3.1% of all CpGs, DNAm decreased from birth and then 
remained stable at 6 years (Negative-Neutral; Figure 3e). The remaining 3.0% of all CpGs followed 
other nonlinear trajectories (e.g. Figure 3f), with each trajectory observed in <1.0% of all CpGs. 
Overall, linear and/or nonlinear changes in Model 1 or 2 were observed in 52.6% of CpGs (Figure 3), 
indicating that most nonlinear patterns were also detected as linear patterns in Model 1. 
 Inter-individual differences in change (i.e. random variance in slopes) from birth onward was 
detected at 3.4% of all sites (Figure 3g), inter-individual differences in slope change at 6 years in 0.2% 
(Figure 3h), and inter-individual differences in slope change at 9 years at 8.2% of CpGs (Figure 3i). 
Inter-individual differences in slope (change) at each time-point were detected more often at CpGs 
with an increasing rather than decreasing overall DNAm change in Model 1 (P=2.37x10-144). Last, both 
Positive-Neutral and Negative-Neutral changes coincided more often with inter-individual variation 
from birth (P<9.88x10-324). Any inter-individual differences in change, detected by Model 1 or 2, was 
observed at 27.9% of CpGs. In total, Models 1 and 2 detected age-related change whether linear, 
non-linear or inter-individual differences in change at 62.8% of all CpG sites (Figure 3).  
 
Sex differences in longitudinal DNAm and DNAm change 
According to Model 3 (online Methods), sex differences in DNAm were present at 4.9% of 
(autosomal) CpGs (Figure 3). Specifically, stable longitudinal sex differences (main sex effects) were 
observed at 4.8% of all (autosomal) CpGs (Figure 3j), and sex differences in DNAm change (sex by age 
interaction effects) were found at 0.4% of all (autosomal) CpGs (Figure 3k). At sites with stable sex 
differences, DNAm levels were higher in girls at 3.6% (Figure 3j) and lower at 1.2% of CpG sites. 
DNAm at sites with higher DNAm in girls tended to increase over time, whereas DNAm at sites with 
higher DNAm in boys tended to decrease (P=4.20x10-205). Most commonly (at 0.2% of all CpGs), 
DNAm was higher in girls at birth but DNAm in boys increased at a higher rate.  
 Both CpGs with stable sex differences and those with sex differences in DNAm change were 
less likely to show inter-individual variation than other sites (20.8% versus 27.5% and 18.1% versus 
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27.3%; P=5.36x10-111 and P=7.57x10-18). Finally, CpGs with stable sex differences or sex differences in 
DNAm change detected in Model 3 were much more likely to follow an overall Positive-Neutral 
trajectory of DNAm change detected in Model 2 than other CpG sites were (24.2% of CpGs with 
stable sex differences followed a Positive-Neutral trajectory versus 3.8% of other CpGs and 53.9% of 
CpGs with sex differences in DNAm change followed a Positive-Neutral trajectory versus 4.6% of 
other CpGs; P<9.88x10-324, P<9.88x10-324; Figure 3l). Albeit less prominently so, CpGs with stable sex 
differences or sex differences in DNAm change also more often followed a Negative-Neutral 
trajectory than other CpGs did (stable sex differences: 5.0% versus 3.0%, P=5.43x10-62; sex 
differences in DNAm change: 7.7% versus 3.1%, P<7.11x10-28).  
 
Follow-up analyses 
Follow-up analyses were performed to understand how different types of age-related DNAm 
trajectories are distributed across the genome (Supplementary Tables 3-5). All reported enrichments 
have significance below a Bonferroni-corrected threshold of P<4.46x10-04, corrected for the number 
of chi-square tests (n=112). We further report enrichment of Gene Ontology (GO) pathways (nominal 
P<0.05) for genes annotated to CpG sites in each trajectory (Supplementary Tables 5-7). Last, we 
study enrichment of age-related DNAm trajectories in reported hits of different EWASs (Figure 6). All 
reported EWAS enrichments are below a Bonferroni-corrected threshold of P<2.16x10-04, corrected 
for the number of Fishers’ exact tests (n=231; Supplementary Table 8).  
 
Patterns of DNAm change and CpG location 
CpG sites with DNAm change associated patterns were labeled by gene associated regions, CpG 
island associated regions, as well as enhancer elements. Although many exceptions exist, low levels 
of DNAm in the promoter area but high levels of DNAm in the gene body are generally associated 
with increased gene transcription32,33. CpGs annotated to TSS200 regions more often showed an 
overall DNAm increase (Model 1) than other CpGs (19.0% versus 15.6%), whereas CpGs annotated to 
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the gene body more often showed an overall DNAm decrease than other sites (38.8% versus 33.7%). 
TSS200 CpGs showed less inter-individual variation in overall DNAm change than other sites (22.2% 
versus 28.1%), whereas gene body CpGs showed somewhat more inter-individual variation in overall 
DNAm change than other sites (28.9% versus 26.5%). 
Promoter areas often coincide with CpG islands34. Here, 63.3% of TSS200 CpGs were also 
annotated to CpG islands. As in TSS200 areas, CpGs annotated to CpG islands had lower DNAm levels 
(mode M1 intercept 2.4% (SD=30.2%)), and more often showed an overall DNAm increase than other 
sites (25.2% versus 12.0%). DNAm sex differences were especially present in the shores of CpG 
islands compared to all other island associated regions (stable sex differences: 7.5% versus 4.0%, sex 
differences in DNAm change: 0.6% versus 0.3%).  
 Enhancers act on promoters to regulate gene transcription35. CpGs annotated to enhancer 
elements (2.0% of CpGs) tended to have low DNAm levels (mode M1 intercept 5.07%; SD=31.4%) and 
then increased with age more than other CpGs (23.9% versus 15.9%). Inter-individual variation in 
change from birth was more common at enhancer sites than at other sites (5.6% versus 3.3%).  
  
Functional associations 
Enrichment of Gene Ontology categories was tested for genes linked to CpGs with different DNAm 
trajectories. In short, genes annotated to CpGs with overall decreasing DNAm levels were enriched in 
immune-developmental functions, whereas those annotated to CpGs with increasing levels were 
enriched in neurodevelopmental functions. This pattern seemed even more pronounced at genes 
annotated to nonlinear Negative-Neutral and Positive-Neutral CpGs, with the former more often 
associated to immune-development and the latter to neurodevelopment. Genes linked to CpGs with 
stable sex differences and sex differences in DNAm change were enriched in pathways associated 
with sexual development, such as genital development, as well as pathways associated with 
neurodevelopment. Genes linked to CpGs with sex difference in DNAm change were also enriched in 
functions related to tooth and hair development.  
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Enrichment in EWASs 
We further investigated functional relevance of CpG sites with age-related DNAm trajectories by 
testing enrichment with published EWAS associations (Figure 6)28,36-61. Unsupervised clustering of the 
enrichments shows that CpG sites with inter-individual variation in change over time have distinct 
enrichments and cluster differently from those with age-associated change that is consistent among 
individuals. The CpG sites of each age-associated DNAm trajectory were enriched with published age 
associations in adulthood. Multiple smoking EWAS clustered together with enrichment patterns 
exhibiting strongest enrichments among CpG sites with Negative-Neutral trajectories and mostly 
weak enrichments among CpG sites with inter-individual variation in change. Further, despite 
adjusting for cell count heterogeneity in our models, we observed enrichments of CpG sites that 
differ by white blood cell type among sites following nearly all age-associated trajectories. Finally, we 
observed enrichments of CpG sites associated with gestational age and prenatal smoking with sex-
specific DNAm.  
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In this study we described changes in DNAm levels through the first two decades of human life. We 
examined DNAm levels per CpG by their linear association with age, their nonlinear trajectories and 
inter-individual variation in change, as well as sex differences and CpG characteristics.  
We found that about half of sites change: consistent linear and/or nonlinear DNAm change was 
found at 53% of sites. We further found that over a quarter of sites, 28%, were characterized by 
substantial inter-individual differences in the direction of this change. DNAm sex differences were 
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present, but not abundant: 5% of autosomal sites displayed different DNAm levels or differences in 
change over time for girls and boys. 
Specifically, we determined that DNAm at 52% of the measured methylome have some form 
of linear change from birth to late adolescence, with DNAm decreasing at 36% and increasing at 16% 
of CpGs. CpGs with decreasing DNAm tended to have high levels of DNAm and were more often 
located in gene bodies. CpGs with increasing levels of DNAm tended to have low levels of DNAm and 
were more likely to be located in promoter regions and at enhancers. The predominance of 
decreasing CpGs is in agreement with literature on epigenome-wide DNAm and age in cross-sectional 
research on children and adults18,62, as well as with longitudinal research in adults19.  
 Nonlinear DNAm trajectories were detected at 11% of CpGs, mostly involving changes in 
DNAm from birth to age 6 years, after which DNAm was more stable. We note that this could be due 
to cord blood being used to generate DNAm profiles at birth, whereas peripheral blood was used at 
later ages. A previous study23 including eight children showed that the cord blood DNAm profile at 
birth clustered separately from later peripheral profiles, after which DNAm changed gradually from 1, 
to 2.5, to 5 years. Such differences between DNAm in cord and peripheral blood might be due to 
uncaptured differences in white blood cell composition, as well as to different gene-regulatory 
functioning in the intra-uterine versus extra-uterine environment. On the other hand, Gene Ontology 
analyses showed that functional associations for positive and negative linear DNAm patterns, which 
are unlikely to be affected by tissue type, were consistent with functional associations for nonlinear 
positive and negative patterns, respectively (e.g. positive and negative up to 6 years, and then no 
change up to 18 years).  
Specifically, sites with decreasing levels of DNAm, both with or without slope changes around 
the age of 6 years, were functionally enriched for immune-developmental pathways, and sites with 
increasing levels of DNAm, both with or without slope changes, were enriched for 
neurodevelopmental pathways. Since these observations were based on blood DNAm, it remains to 
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be studied what roles genes linked to neurodevelopmental pathways play in in blood, or to what 
extent DNAm trajectories in blood mirror those in neural tissue.  
 Inter-individual differences in linear DNAm trajectories were found at 27% of CpGs, indicating 
change at different rates or directions for different individuals. Such sites tended to have overall 
increasing rather than decreasing levels of DNAm from birth to 18 years. This observation is 
consistent with the only other large study to examine inter-individual differences in DNAm change20, 
although we note that this study included elderly subjects and detected a smaller number of relevant 
CpGs. We are the first to investigate inter-individual differences in nonlinear DNAm trajectories. 
These were most often found in the slope change at 9 years (8% of CpG sites), indicating that most 
inter-individual differences in DNAm emerge after the first decade of life. More research is needed to 
understand if the direction of change in this period is determined by stimuli during that period, or 
rather by preceding, perhaps cumulative, exposures. However, it is clear that, given the high 
proportion of CpG sites with inter-individual variation in DNAm change over time that we have 
observed, it is important to restrict the range of ages of children included a single EWAS. Specific 
limits should be discussed given the rapidly growing number of studies generating DNAm profiles 
across childhood63. 
 Stable sex differences were found at 5% of autosomal CpGs, and sex differences in DNAm 
change were found at 0.4% of all CpGs. In general, if there were stable sex differences, girls had 
higher levels of DNAm (4% of all CpGs), in case of sex differences in DNAm change, boys had an 
accelerated upward change (0.2% of all CpGs). The direction of stable sex differences detected are 
congruent with a cross-sectional study on newborns, in which girls had higher DNAm levels than boys 
for the large majority of the 3031 significant autosomal CpGs54. Sex-discordant associations with age 
seemed to be more prevalent from birth to age 6 years than afterwards, suggesting that any 
phenotypic sex differences associated to DNAm would be established in early childhood. Their 
enrichment in the shores of CpG islands, areas at which DNAm has been associated with tissue 
differentiation and tissue-specific gene expression64, is consistent with the critical role that these 
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processes play in sexual differentiation. Studies into sex differences in epigenetic regulation might 
want to focus on these locations.  
 We also found the other DNAm trajectories to be arranged throughout the genome in a 
nonrandom fashion. Earlier studies32,65 have shown that, for active genes, lower DNAm towards the 
promoter area (TSS200) and higher DNAm in the gene body relate to increased gene transcription. 
Here we add the observation that promoter DNAm tends to increase and gene body DNAm tends to 
decrease with age. From this finding, one might infer that a downregulation of gene expression takes 
place from birth to late adolescence. Enrichment analyses of published EWAS associations further 
showed that different traits and exposures exhibited distinct enrichment patterns among DNAm 
trajectories. For example, there were clear differences between smoking and BMI-related traits. 
Enrichment of sites with DNAm sex differences in EWASs on prenatal maternal smoking is consistent 
with studies finding that prenatal smoking affects traits such as birth weight66 , brain 
development67,68, and attention69 differently in boys and girls. Clustering for prenatal maternal 
smoking EWASs also showed enrichment for CpGs with consistent change among individuals, not for 
CpGs with inter-individual variation in change. This may suggest a link with the well-known effects of 
prenatal smoking on childhood development since consistent DNAm change is more likely related to 
development or aging programming than inter-individual variation. This may explain why changes 
associated to prenatal smoking persist throughout life70. Notably, this pattern of change without 
inter-individual variation is visible in cg05575921, the AHRR CpG site strongly and persistently 
associated with prenatal smoking71,72 (Supplemental Figure 2; http://epidelta.mrcieu.ac.uk/).  
‘Epigenetic age acceleration’ is a term coined to indicate the deviation of chronological age 
from age as estimated by an ‘epigenetic clock’ and is associated with disease risk and mortality73. 
Existing clocks are all linear models based on DNAm. Consequently, one might expect that all CpGs 
included in the clock model change linearly with age. Furthermore, to detect age acceleration, one 
would expect that these CpG sites would also vary between individuals. Surprisingly, many CpG sites 
included in the most popular clocks do not match these expectations74,75 (Supplemental Tables 9, 10). 
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For example, we observe that over one-quarter and nearly one-half of the CpG sites included in the 
Horvath and Hannum clocks, respectively, follow non-linear DNAm trajectories in childhood. Given 
the widespread use of clocks to investigate biological aging, further investigation is warranted to 
better understand how, and perhaps if, associations using these clocks should be interpreted in child 
DNAm profiles. 
 We note three main limitations of our findings. First, the use of different tissue types (cord 
blood and peripheral blood) could account for some of the differences between birth and later time 
points, e.g. sites that increased or decreased between birth and 6, but did not show change after 
that. Generation of DNAm profiles of a single tissue or cell type collected across childhood would be 
needed to disentangle this issue further. Unfortunately, such a dataset is not currently available as  
most cohorts have generated DNAm profiles from peripheral blood and cord blood63. Analysis of 
these complex tissues has nevertheless yielded many valuable insights. Second, since DNAm at 9 
years was measured only in Generation R and at 17 years only in ALSPAC, DNAm differences from 9 
to 17 may be to some extent driven by batch effects or cohort differences. This may explain some of 
the inter-individual differences in slope changes at 9 towards 17 years. However, the high level of 
agreement in both stability and change among the corresponding time points of the two cohorts is 
reassuring. Moreover, it is not entirely surprising that inter-individual variation in directionality of 
change was higher for the largest age interval. This interval, furthermore, encompasses the period of 
adolescent development, a time in which many inter-individual phenotypic differences arise. Finally, 
it should be noted that the current study only included children of European ancestry. Considerable 
DNAm differences have been found between populations76-78, but research on age-associated DNAm 
differences is scarce. One study79 reported evidence for overlap in age-associated CpGs in two 
African populations with studies on European-ancestry populations, but more research is needed to 
map the generalizability of longitudinal DNAm changes among different populations.  
 In conclusion, in the first comprehensive CpG-by-CpG characterization of DNAm from birth to 
late adolescence, we found that DNAm at more than half of the studied CpG sites changes 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted June 10, 2020. ; https://doi.org/10.1101/2020.06.09.142620doi: bioRxiv preprint 
20 
 
consistently between individuals, and that considerable inter-individual variation in change exists. 
Further, characteristics such as child sex, CpG location, and environmental and disease traits have 
distinct associations with patterns of DNAm change. Further analysis of these patterns is made 
readily available at http://epidelta.mrcieu.ac.uk/, which we hope can be used in future studies to test 
developmental hypotheses that promote our understanding of the developmental nature of DNAm, 





Data were obtained from two population-based prospective birth cohorts, the Dutch Generation R 
Study (Generation R) and the British Avon Longitudinal Study of Parents and Children (ALSPAC). 
Pregnant women residing in the study area of Rotterdam, the Netherlands, with an expected delivery 
date between April 2002 and January 2006 were invited to enroll in Generation R. A more extensive 
description of the study can be found elsewhere80. The Generation R Study is conducted in 
accordance with the World Medical Association Declaration of Helsinki and has been approved by 
the Medical Ethics Committee of the Erasmus Medical Center, Rotterdam. Informed consent was 
obtained for all participants.  
 Pregnant women residing in the study area of former county Avon, United Kingdom, with an 
expected delivery date between April 1991 and December 1992 were invited to enroll in the ALSPAC 
study. Detailed information on the study design can be found elsewhere3,81. The ALSPAC website 
contains details of all available data through a fully searchable data dictionary and variable search 
tool (http://www.bristol.ac.uk/alspac/researchers/our-data/). Ethical approval for the study was 
obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. 
Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). 
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Informed consent for the use of data collected via questionnaires and clinics was obtained from 
participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.  
 
Study Population 
In the Generation R Study, 9,778 pregnant mothers had 9,749 live-born children. For a subsample of 
1,414 children DNAm data was collected at birth and/or 6 years and/or 10 years of age. This 
subsample consisted of participants with parents born in the Netherlands (European ancestry82 
confirmed for all children with genetic data available (95.4%)). Fifteen sibling pairs were present in 
the dataset. From each pair one sibling with the lowest number of DNAm measurements, or 
otherwise randomly, was excluded, resulting in a sample with 1,399 children (with 2,333 DNAm 
samples; see below). 
 In the ALSPAC study, 15,247 pregnant mothers gave birth to 14,973 live-born children. DNAm 
at birth and/or 7 years and/or 17 years was available for a subsample of 1,003 children as part of the 
Accessible Resource for Integrated Epigenomic Studies (ARIES) study83. From this sample, 48 children 
with non-European ancestry as based on genetic principle component analysis and 6 children with 
missing data on gestational age were excluded, resulting in a sample of 949 children with DNAm data 
(with 2,686 DNAm samples; see below).  
 
DNA methylation 
Cord blood was drawn after birth for both cohorts, and peripheral blood was drawn at a mean age of 
6.0 (SD=0.47) and 9.8 (SD=0.3) years for Generation R, and 7.5 (SD=0.2) and 17.1 (SD=1.0) years for 
ALSPAC. Both cohorts made use of the EZ-96 DNAm kit (shallow) (Zymo Research Corporation, Irvine, 
USA) to perform bisulfite conversion on the extracted leukocytic DNA. Samples were further 
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processed with the Illumina Infinium HumanMethylation450 BeadChip (Illumina Inc., San Diego, USA) 
to analyze DNAm.  
 In Generation R, quality control was performed on all 2,467 available DNAm samples with the 
CPACOR workflow84. Arrays with observed technical problems such as failed bisulfite conversion, 
hybridization or extension, as well as arrays with a mismatch between sex of the proband and sex 
determined by the chromosome X and Y probe intensities were removed from subsequent analyses. 
Additionally, only arrays with a call rate >95% per sample were processed further, resulting in 2,355 
samples, 22 of which belonged to half of an excluded sibling pair, hence 2,333 samples were carried 
forward into normalization.  
 In ALSPAC, quality control was performed on 6,057 samples (3,286 belonging to children, 
2,771 to their mothers), using the meffil package85 in R version 3.4.386. After removing samples with 
mismatched genotypes, mismatched sex, incorrect relatedness, low concordance with samples 
collected at other time points, extreme dye bias, and poor probe detection, 5,337 samples remained, 
2,845 of which belonging to children, used in the current study.  
 To minimize cohort effects as much as possible, we normalized both cohorts together as a 
single dataset. Functional normalization (10 control probe principal components, slide included as a 
random effect) was performed with the meffil package in R85. Normalization took place on the 
combined Generation R and ALSPAC set comprising a total of 5,178 samples for a total of 485,512 
CpGs. One-hundred and fifty-nine ALSPAC samples belonging to non-European children or children 
with missing data on gestational age were excluded, leading to a final ALSPAC set of 2,686 samples 
(for 949 children). Together with 2,333 samples for Generation R (of 1,399 children) they formed a 
combined set of 5,019 samples (of 2,348 children.)  
 Analyses were restricted to 473,864 autosomal CpGs. DNAm levels were operationalized as 
beta values (β values), representing the ratio of methylated signal relative to the sum of methylated 
and unmethylated signal measured per CpG.  
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Sample plate number (N=29 in Generation R and N=31 in ALSPAC), was used to correct for batch 
effects, which was added as a random variable in the model (see below). White blood cell (WBC) 
composition was estimated with the reference-based Bakulski method87 for cord blood and 
Houseman method88 for peripheral blood (Supplemental Table 11). Nucleated red blood cells were 
not further analyzed due to its specificity to cord blood, leaving CD4+ T-lymphocytes, CD8+ T-
lymphocytes, natural killer cells, B-lymphocytes, monocytes, and granulocytes. Other covariates 
included gestational age in weeks, sex of the child, and cohort.  
 
Statistical analyses 
Step 1: Assessing cross-cohort comparability in DNA methylation stability 
To ascertain comparability amongst the two cohorts we compared within-cohort DNAm stability 
between the time points that were present in both cohorts – i.e. birth and 6/7 years (Generation 
R/ALSPAC, respectively).  
 Longitudinal stability per CpG within each cohort was assessed by studying estimates of 
concordance and change. For concordance, DNAm data was first residualized within each cohort for 
all variables present in the longitudinal models except the ‘cohort’ variable, in order to remove 
between-cohort differences due to other covariates. Concordance was then measured both with 
Spearman correlation (data at most CpGs is not normally distributed) as a measure of relative 
concordance, and with intra-class correlations as a measure of absolute concordance (children with 
data for both time points: n Generation R=476, n ALSPAC=826). Longitudinal change from birth to 6/7 
years was assessed by studying the estimates of the change in DNAm per year by applying Model 1 
(see below) within each cohort (children with data for at least one of the two time-points: n 
Generation R=1,394, n ALSPAC=944).  
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 In a second step, cross-cohort comparability was assessed with Spearman (ρ) correlation of 
concordance estimates of the CpGs of each cohort (which were not normally distributed) and 
Pearson correlations (r) amongst the change estimates of the CpGs of each cohort (which were 
normally distributed).  
 
Step 2: Longitudinal modelling of DNA methylation using combined Generation R and ALSPAC data 
 The combined Generation R and ALSPAC dataset had four time points of collection (birth, age 
6/ 7 years, 10 years, and 17 years). We fit three linear mixed models to CpG site DNAm across the 
genome to identify (i) linear change over time (Model 1); (ii) nonlinear change over time (Model 2); 
and (iii) sex differences in change over time (Model 3). Both fixed and random effects were examined 
to allow for inter-individual variation in DNAm patterns over time. The models are described in detail 
below.  
 
Model 1: Linear change. This model was applied to identify CpGs that show an overall change in 
DNAm from birth to 18 years (i.e. fixed age effect), as well as CpGs with inter-individual differences in 
change during that time (i.e. random age effect). The Model 1 is defined as:  
 
M1:  Mijk = β0 + u0i + β1Ageij + u1iAgeij + u0k + covariates + ϵijk  
  ϵijk ~ N(0,σϵ2) 
  u0i ~ N(0,σ0i2) 
  u1i ~ N(0,σ1i2) 
  u0k ~ N(0,σ0k2) 
 
Here, participants are denoted by i, time points by j, and sample plates by k. M denotes DNAm level, 
β0 fixed intercept, u0i random intercept, β1 fixed age coefficient, u1i random age coefficient, u0k 
random intercept for sample plate. Hence, β1 represents the average change in DNAm per one year. 
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Variability in this change amongst individuals was captured with u1i. To avoid problems with model 
identification, the random slope of age was uncorrelated to the random intercept (i.e. a diagonal 
random effects matrix was used). 
 
Model 2: Nonlinear change. To identify nonlinear changes in DNAm, we extended Model 1 to allow 
slope changes at ages 6 and 930,31: 
 
M2:  Mijk = β0 + u0i + β1Ageij + β2(Ageij−6)+ + β3(Ageij−9)+ +u1i Ageij + u2i (Ageij−6)+ + u3i   
 (Ageij−9)+ + u0k + covariates + ϵijk 
  ϵijk ~ N(0,σϵ2) 
  u0i ~ N(0,σ0i2) 
  u1i ~ N(0,σ1i2) 
  u2i ~ N(0,σ2i2) 
  u3i ~ N(0,σ3i2) 
  u0k ~ N(0,σ0k2) 
 
Where a+ = a if a>0 and 0 otherwise, so that β2 represents the average change in DNAm per year 
from 6 years of age onward, after accounting for the change per year from birth onward, as denoted 
by β1. Likewise, β3represents the average change in DNAm per year from 9 years of age onward, after 
accounting for the change per year from 6 years of age onward. Hence, with those variables we are 
able to detect slope changes at 6 and 9 years old. These slope changes were used to identify different 
types of nonlinear patterns. With u2i and u3i the inter-individual variation in slope changes at 6 and 9 
years were captured, respectively. General linear hypothesis testing89 was applied to our fitted 
models to determine if there were changes in DNAm per year from 6-9 years and from 9-18 years.  
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 Model 3: Sex differences in change: To identify CpGs for which DNAm changes differently over time 
for boys and girls, we applied the following model: 
  
M3:  Mijk = β0 + u0i + β1Ageij +u1i Ageij + β2SexiAgeij + u0k + covariates + ϵijk  
  ϵijk ~ N(0,σϵ2) 
  u0i ~ N(0,σu2) 
  u1i ~ N(0,σ1i2) 
  u0k ~ N(0,σ0k2) 
 
Here, Sexi denotes the sex of child i. Both main and interaction effects for sex were studied.  
 The three mixed models were fitted using maximum likelihood estimation in R with the lme4 
package90. Continuous covariates (WBCs, gestational age) were z-score standardized. Random slopes 
were kept uncorrelated with random intercepts and the NLopt optimizer was used, enabling us to 
improve computational speed compared to the default settings. P-values for the fixed effects were 
computed with a z-test. P-values for random slopes of the Age effects were obtained by refitting the 
model without the random slope and comparing the fit estimates of the two models with a likelihood 
ratio test. Within each model, P-value thresholds were Bonferroni-corrected for the number of 
tested CpGs (i.e. to P<1x10-07).  
 
Step 3: Functional characterization of probes with comparable patterns of change 
To interpret the functionality of the age-related DNAm patterns from the three models, CpG sites 
adhering to 8 different age-related patterns (M1 linear change and inter-individual variation in linear 
change, M2 nonlinear trajectories, and inter-individual variation in change from birth, in slope 
change at 6 years, and in slope change at 9 years, and M3 stable sex differences and sex differences 
in DNAm change) were tested for enrichment in:  
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(i)  gene-relative genomic regions (TSS1500, TSS200, 5'UTR, 1st exon, gene body, 3'UTR, and 
intergenic regions64),  
(ii)  CpG island-relative genomic regions (N shelf, N shore, CpG island, S shore, S shelf, and open 
sea regions64) as indicated by the Illumina HumanMethylation450 v1.2 Manifest (Illumina 
Inc., San Diego, USA), and 
(iii)  enhancer elements as those expressed in whole blood, peripheral blood mononuclear cells, 
natural killer cells, CD4+ T cells, CD8+ T cells, monocytes, neutrophils, eosinophils or B cells91,  
Altogether, these encompassed 14 enrichment analyses for 8 variables. Enrichment was tested using 
χ2-tests of unequal proportions. The enrichment P-value threshold was Bonferroni-corrected for 
multiple tests (i.e. P<4.46x10-04 for 8x14=122 tests). Second, we tested enrichment of Gene Ontology 
(GO) categories for genes linked to CpG sites surviving adjustment for multiple tests (P<1x10-07) for 
each of the main variables of interest. This analysis was adjusted for gene size and pruned for near-
identical terms (see elsewhere for a full description92). For completeness, terms with nominal P<0.05 
were reported. Last, we tested enrichment of age-related DNAm trajectories (11 different age-
related patterns: M1 decreasing, increasing, and inter-individual variation in linear change, M2 
Positive-Neutral, Negative-Neutral, other nonlinear, inter-individual variation in change from birth, in 
slope change at 6 years, and in slope change at 9 years, and M3 stable sex differences and sex 
differences in DNAm change) in EWASs on age, prenatal smoking, smoking, cardiovascular-associated 
traits, C-reactive protein, allergies, educational attainment, and cellular heterogeneity. EWAS 
summary statistics were retrieved from the EWAS Catalog (http://www.ewascatalog.org/) and studies 
were included when performed with the 450K array in peripheral or cord blood, resulting in 21 
EWASs. Enrichment was tested with Fisher’s exact tests, the enrichment P-value threshold was 
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Data from the Generation R Study are available upon request (generationr@erasmusmc.nl), subject 
to local rules and regulations. ALSPAC data access is through a system of managed open access. The 
ALSPAC access policy (http://www.bristol. ac.uk/media-library/sites/alspac/documents/researchers/ 
data-access/ALSPAC_Access_Policy.pdf) describes the process of accessing the data and samples in 
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